Gene therapy for liver enzyme deficiencies: what have we learned from models for Crigler-Najjar and tyrosinemia?
The liver is the site of numerous metabolic inherited diseases. It has unique features that make it compliant to various gene therapy approaches. Many vector types and gene delivery strategies have been evaluated during the past 20 years in a number of animal models of metabolic liver diseases. However, the complete cure of inherited liver deficiencies by gene therapy in relevant animal models were only reported recently. These successes were achieved thanks to major advances in vector technology. In this review, we will focus on Crigler-Najjar disease and hereditary tyrosinemia, two paradigmatic examples of the two categories of enzymatic liver deficiencies: type I, in which the genetic defect does not affect liver histology; and type II, in which liver lesions are present.
Nguyen
Tuan Huy
TH
INSERM CIC-00-04 Biothérapies Hépatiques, CHU Hôtel-Dieu, 44035 Nantes Cedex, France. tuan.nguyen@univ-nantes.fr
Ferry
Nicolas
N
D000818:Animals; D003414:Crigler-Najjar Syndrome / Q000628:therapy*; D004195:Disease Models, Animal; D015316:Genetic Therapy; D014453:Glucuronosyltransferase / Q000172:deficiency; D006801:Humans; D014444:Tyrosine Transaminase / Q000172:deficiency; D020176:Tyrosinemias / Q000628:therapy*
D014453:Glucuronosyltransferase; D014444:Tyrosine Transaminase